James L Januzzi1, Javed Butler2, Emmanuel Fombu3, Alan Maisel4, Kevin McCague3, Ileana L Piña5, Margaret F Prescott3, Jerome B Riebman3, Scott Solomon6. 1. Massachusetts General Hospital, Boston, MA; Baim Institute for Clinical Research, Boston, MA. Electronic address: JJanuzzi@partners.org. 2. Health Institute, Stony Brook University, Stony Brook, NY. 3. Novartis Pharmaceuticals, East Hanover, NJ. 4. University of California, San Diego School of Medicine, San Diego, CA. 5. Montefiore Medical Center, Bronx, NY. 6. Harvard Medical School, Brigham and Women's Hospital, Boston, MA.
Abstract
BACKGROUND:Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor indicated for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; however, its mechanism of benefit remains unclear. Biomarkers that are linked to ventricular remodeling, myocardial injury, and fibrosis may provide mechanistic insight and important clinical guidance regarding sacubitril/valsartan use. METHODS: This 52-week, multicenter, open-label, single-arm study is designed to (1) correlate biomarker changes with cardiac remodeling parameters, cardiovascular outcomes, and patient-reported outcome data and (2) determine short- and long-term changes in concentrations of biomarkers related to potential mechanisms of action and effects of sacubitril/valsartan therapy. Approximately 830 patients with HF with reduced ejection fraction will be initiated and titrated on sacubitril/valsartan according to United States prescribing information. Primary efficacy end points include the changes in N-terminal pro-B-type natriuretic peptide concentrations and cardiac remodeling from baseline to 1 year. Secondary end points include changes in concentrations of N-terminal pro-B-type natriuretic peptide and remodeling to 6 months, and changes in patient-reported outcomes using the Kansas City Cardiomyopathy Questionnaire-23 from baseline to 1 year. In addition, several other relevant biomarkers will be measured. Biomarker changes relative to the number of cardiovascular events in 12 months will also be assessed as exploratory end points. CONCLUSIONS: Results from the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) will help establish a mechanistic understanding of angiotensin receptor-neprilysin inhibitor therapeutic benefits and provide clinicians with clarity on how to interpret information on biomarkers during treatment (PROVE-HF ClinicalTrials.gov identifier: NCT02887183).
RCT Entities:
BACKGROUND:Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor indicated for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; however, its mechanism of benefit remains unclear. Biomarkers that are linked to ventricular remodeling, myocardial injury, and fibrosis may provide mechanistic insight and important clinical guidance regarding sacubitril/valsartan use. METHODS: This 52-week, multicenter, open-label, single-arm study is designed to (1) correlate biomarker changes with cardiac remodeling parameters, cardiovascular outcomes, and patient-reported outcome data and (2) determine short- and long-term changes in concentrations of biomarkers related to potential mechanisms of action and effects of sacubitril/valsartan therapy. Approximately 830 patients with HF with reduced ejection fraction will be initiated and titrated on sacubitril/valsartan according to United States prescribing information. Primary efficacy end points include the changes in N-terminal pro-B-type natriuretic peptide concentrations and cardiac remodeling from baseline to 1 year. Secondary end points include changes in concentrations of N-terminal pro-B-type natriuretic peptide and remodeling to 6 months, and changes in patient-reported outcomes using the Kansas City Cardiomyopathy Questionnaire-23 from baseline to 1 year. In addition, several other relevant biomarkers will be measured. Biomarker changes relative to the number of cardiovascular events in 12 months will also be assessed as exploratory end points. CONCLUSIONS: Results from the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) will help establish a mechanistic understanding of angiotensin receptor-neprilysin inhibitor therapeutic benefits and provide clinicians with clarity on how to interpret information on biomarkers during treatment (PROVE-HF ClinicalTrials.gov identifier: NCT02887183).
Authors: James L Januzzi; Tariq Ahmad; Hillary Mulder; Adrian Coles; Kevin J Anstrom; Kirkwood F Adams; Justin A Ezekowitz; Mona Fiuzat; Nancy Houston-Miller; Daniel B Mark; Ileana L Piña; Gayle Passmore; David J Whellan; Lawton S Cooper; Eric S Leifer; Patrice Desvigne-Nickens; G Michael Felker; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2019-09-03 Impact factor: 24.094
Authors: Peder Langeland Myhre; Muthiah Vaduganathan; Brian Claggett; Milton Packer; Akshay S Desai; Jean L Rouleau; Michael R Zile; Karl Swedberg; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon Journal: J Am Coll Cardiol Date: 2019-03-04 Impact factor: 24.094
Authors: Maria Tafelmeier; Andrea Baessler; Stefan Wagner; Bernhard Unsoeld; Andrej Preveden; Fausto Barlocco; Alessia Tomberli; Dejana Popovic; Paul Brennan; Guy A MacGowan; Arsen Ristic; Lazar Velicki; Iacopo Olivotto; Djordje G Jakovljevic; Lars S Maier Journal: Clin Cardiol Date: 2020-03-03 Impact factor: 2.882
Authors: Alexander J Blood; Christina M Fischer; Liliana E Fera; Taylor E MacLean; Katelyn V Smith; Jacqueline R Dunning; Joshua W Bosque-Hamilton; Samuel J Aronson; Thomas A Gaziano; Calum A MacRae; Lina S Matta; Ana A Mercurio-Pinto; Shawn N Murphy; Benjamin M Scirica; Kavishwar Wagholikar; Akshay S Desai Journal: Clin Cardiol Date: 2019-11-14 Impact factor: 2.882